Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive surprises than negative ones.

Trump Media shares dipped after launching its AI-powered Truth Search beta with Perplexity, even as the company reported $3.1 ...

Q2 2025 Management View John G. Houston, Chairperson, CEO & President, stated the quarter was eventful with "significant clinical and regulatory programs across our pipeline of PROTAC degraders." He ...

Research and development expenses fell 48.2% compared to Q2 2024, while general and administrative costs rose 121.1%, Research and development expenses were $1.0 million compared to $2.1 million for ...

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to ...

While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

Pfizer Inc displayed a robust performance in its Q2 2025 earnings call, with significant strides in revenue and research ...

Moreover, data on Tuesday showed that the U.S. trade deficit narrowed by more than anticipated in June, reflecting a dip in ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

Central to Nxera’s pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from ...